- Home
- RDI vs CVM Comparison
RDI vs CVM Comparison
Compare RDI & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDI | CVM |
|---|---|---|
| Founded | 1937 | 1983 |
| Country | United States | United States |
| Employees | 2005 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 21.4M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | RDI | CVM |
|---|---|---|
| Price | $1.22 | $1.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.6K | ★ 735.3K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | $16.25 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.94 | $0.89 |
| 52 Week High | $1.65 | $13.48 |
Technical Indicators
Market Signals| Indicator | RDI | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 36.81 |
| Support Level | $0.99 | $0.89 |
| Resistance Level | $1.26 | $1.86 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 65.22 | 45.52 |
Price Performance
Historical ComparisonAbout RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.